A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting

Sponsor
Hoffmann-La Roche
Study ID
NCT01664104
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.

Study Details

This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of tocilizumab therapy in a routine clinical practice in participants with moderate to severe rheumatoid arthritis (RA). Data will be collected for 6 months with a maximum study duration of 18 months.

Key Dates

Start date
Jun 30, 2012
Status verified
Apr 2017
Primary completion
Dec 31, 2013
Completion
Dec 31, 2013

Study Design

Enrollment
151 participants (actual)

Arms

  • Arm: RA Participants
    Participants with moderate or severe RA who are under tocilizumab treatment in routine clinical practice (in accordance with the local label) will be observed for 6 months from the start of treatment.

Primary Outcome Measure

Percentage of Participants on TCZ Treatment at Month 6 [ Time Frame: Month 6 ]

Related Studies